Trial reportMedicine2025
Effect of thoracic paravertebral block with ropivacaine and compound betamethasone on postoperative pain after thoracoscopic surgery: A randomized, double-blind, controlled trial.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose was to evaluate the effect of thoracic paravertebral block (TPVB) with a combination of ropivacaine and compound betamethasone on postoperative pain in patients undergoing thoracoscopic surgery.
methodsA randomized, double-blind, controlled trial was conducted. A total of 100 patients undergoing elective thoracoscopic pulmonary lesion resection were randomly divided into 2 groups: the ropivacaine group (group R) and the ropivacaine combined with compound betamethasone group (group RD). The pain intensity at rest/coughing was assessed by the Visual Analogue Scale (VAS) at different times. The incidence of pain (VAS ≥ 1) at 1-, 3-, and 6-month follow-up was recorded. The anesthetic dosage, adverse effects, and postoperative recovery parameters were also observed.
resultsCompared to group R, group RD demonstrated a significant reduction in additional patient-controlled intravenous analgesia pump presses at 24 hours postoperatively and significantly lower VAS scores at rest/coughing after extubation, and at 6, 12, 24, 48, 72 hours, and 1-month postoperatively (P <.05). Group RD reduced the incidence of pain at 1, 3, and 6 months postoperatively more than group R (P <.05), as well as in postoperative nausea, vomiting, and drowsiness. No statistically significant differences were observed between the 2 groups regarding postoperative blood glucose levels, duration of drainage tube placement, time to first mobilization, and length of hospital stay.
conclusionThese results suggest that the combination of ropivacaine and compound betamethasone in TPVB effectively reduces both acute and chronic postoperative pain after thoracoscopic surgery. It also decreases the incidence of postoperative adverse reactions, making it a superior adjuvant for TPVB with local anesthetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.